Clinics in Dermatology
Volume 25, Issue 6 , Pages 547-554 , November 2007

Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience

  • Gerhard Schmid-Ott, MD

      Affiliations

    • Department of Psychosomatic Medicine, Hanover Medical School, D-30625 Hanover, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 511 532 6569; fax: +49 511 532 3190.
    • ,
  • Sabine Schallmayer, M Psych Sc

      Affiliations

    • Department of Psychosomatic Medicine, Hanover Medical School, D-30625 Hanover, Germany
    • ,
  • Iris Tatjana Calliess, MD

      Affiliations

    • Department of Social Psychiatry and Psychotherapy, Hanover Medical School, D-30625 Hanover, Germany

References 

  1. Holsinger L. A battle with my skin. J Am Acad Dermatol. 2004;51:41–42
  2. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912
  3. Buske-Kirschbaum A, Ebrecht M, Kern S, et al. Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)—do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)?. Psychoneuroendocrinology. 2006;31:439–446
  4. Schmid-Ott G, Jäger B, Boehm T, et al. Different stress-induced membrane molecule profile of circulating lymphocytes in patients with psoriasis and healthy controls. Psychother Psychos Med Psychol. 2006;56:104
  5. Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204
  6. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24:438–447
  7. Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9:40–46
  8. Galadari I, Sharif MO, Galadari H. Psoriasis: a fresh look. Clin Dermatol. 2005;23:491–502
  9. Crosby IA. My skin is only the top layer of the problem. Arch Dermatol. 1995;131:783–785
  10. Finlay AY, Khan GK. Dermatology Life Quality Index DLQI: a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216
  11. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407
  12. Perrott SB, Murray AH, Lowe J, et al. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000;70:567–571
  13. Wahl A, Loge JH, Wiklund I, et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol. 2000;43:803–808
  14. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–284
  15. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144:967–972
  16. Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: an analysis of reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom. 2003;3:171–179
  17. Vardy D, Besser A, Amir M, et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002;147:736–742
  18. De Korte J, Mombers FM, Sprangers MA, et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002;138:1221–1227
  19. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002;82:108–113
  20. Schmid-Ott G, Burchard R, Niederauer HH, et al. Stigmatization experience and the quality of life of patients with psoriasis and atopic dermatitis. Hautarzt. 2003;54:852–857
  21. Lewis VJ, Finlay AY. A critical review of quality-of-life scales for psoriasis. Dermatol Clin. 2005;23:707–716
  22. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol. 2005;152:1256–1262
  23. Schmid-Ott G, Kuensebeck HW, Jaeger B, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol. 2005;85:27–32
  24. Nast A, Kopp I, Augustin M, et al. German S3—guideline for the treatment of psoriasis vulgaris–short version. JDDG. 2006;[submitted]
  25. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54:685–704
  26. Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol. 2006;24:33–42
  27. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75:240–243
  28. Schmid-Ott G, Kuensebeck HW, Jaeger B, et al. Validity study for the stigmatization experience in atopic dermatitis and psoriasis patients. Acta Derm Venereol. 1999;79:443–447
  29. Scharloo M, Kaptein AA, Weinman J, et al. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol. 2000;142:899–907
  30. Fortune DG, Richards HL, Main CJ, et al. Patients' strategies for coping with psoriasis. Clin Exp Dermatol. 2002;27:177–184
  31. Fortune DG, Richards HL, Griffiths CE, et al. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol. 2002;41:157–174
  32. Davidsson S, Blomqvist K, Molin L, et al. Lifestyle of Nordic people with psoriasis. Int J Dermatol. 2005;44:378–383
  33. Nijsten T, Rolstad T, Feldman SR, et al. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol. 2005;141:19–26
  34. Schmid-Ott G, Malewski P, Kreiselmaier I, et al. Psychosocial consequences of psoriasis—an empirical study on the burden of skin disease in 3753 patients. Hautarzt. 2005;56:466–472
  35. Dubertret L, Mrowietz U, Ranki A, et al. EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;55:729–736
  36. Richards HL, Fortune DG, Griffiths CE, et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50:11–15
  37. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073–3080
  38. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022
  39. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390
  40. Van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol. 2004;151:663–668
  41. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954–960
  42. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289
  43. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238–249
  44. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043
  45. Zink A, Thiele K, Huscher D, et al. German Collaborative Arthritis Centres. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33:86–90
  46. Schmid-Ott G, Jaeger B, Kuensebeck HW, et al. Dimensions of stigmatization in patients with psoriasis in a “Questionnaire on Experience with Skin Complaints”. Dermatology. 1996;193:304–310
  47. Schmid-Ott G, Jaeger B, Kuensebeck HW, et al. Psychosocial influences on the illness experience of psoriasis patients. A study with the “Questionnaire on Experience with Skin Complaints (QES)”. Zeitschr Klin Psychol Psychiat Psychoth. 1998;46:330–343
  48. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20:53–63
  49. Fortune DG, Main CJ, O'Sullivan TM, et al. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res. 1997;42:467–475
  50. Sorensen AS, Hansen H, Andersen R, et al. Personality characteristics and epilepsy. Acta Psychiatr Scand. 1989;80:620–631
  51. Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol. 1993;32:587–591
  52. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236–244
  53. Kent G, Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol. 1996;21:330–333
  54. Schmid-Ott G, Jaeger B, Kuensebeck HW, et al. Illness attitudes and help seeking of psoriasis patients. Hautarzt Der. 1997;48:547–555
  55. Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis. 1998;61:339–342
  56. Leary MR, Rapp SR, Herbst KC, et al. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol. 1998;17:530–536
  57. Schmid-Ott G, Malewski P, Kuensebeck HW, et al. Illness-related stress in psoriasis vulgaris. Validation of the “Psoriasis Daily Stress Inventory”. Hautarzt. 2000;51:496–501
  58. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–518
  59. Nijsten T, Unaeze J, Stern RS. Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis. Br J Dermatol. 2006;154:692–700
  60. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol. 2006;126:1438–1440
  61. Grob JJ, Revuz J, Ortonne JP, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289–295
  62. Fredriksson T, Petersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157:238–244
  63. Feldman SR, Fleischer AB, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106:183–186
  64. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured education programmes improve the management of atopic dermatitis in children and adolescents: results of the German Atopic Dermatitis Intervention Study (GADIS). Br Med J. 2006;332:933–938
  65. Bonnekoh B, Schmid-Ott G, Herold S, et al. Interdisciplinary block school-program for educational psoriasis prevention in adult patients: a half-year follow-up. Hautarzt. 2006;57:917–922

PII: S0738-081X(07)00152-6

doi: 10.1016/j.clindermatol.2007.08.008

Clinics in Dermatology
Volume 25, Issue 6 , Pages 547-554 , November 2007

Article Tools